Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Incorporated
New Intellectual Property Patent for Advaxis Issued
February 27th, 2009
The U.S. Patent and Trademark Office (USPTO) issued today patent 7,488,487 “Methods of Inducing Immune Response Through the Administration of Auxotrophic Attenuated DAL/DAT Double Mutant Listeria Strains,” by Dr. Fred Frankel, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS). Advaxis developed this work as a new strain of the bacterium Listeria monocytogenes (Lm), currently in laboratory testing, which is to be used in Advaxis’ second generation of live Listeria vaccines. In preliminary testing, this strain appears to be less virulent and more immunogenic than prior strains. ...
Source: Health Business Week (2009-02-27)
|
